Influence of Intravesical Bacillus Calmette-Guerin Therapy on Systemic Immunological Status
Article first published online: 1 JUL 2007
International Journal of Urology
Volume 4, Issue 5, pages 456–460, September 1997
How to Cite
Yoshimura, K. and Yamauchi, T. (1997), Influence of Intravesical Bacillus Calmette-Guerin Therapy on Systemic Immunological Status. International Journal of Urology, 4: 456–460. doi: 10.1111/j.1442-2042.1997.tb00285.x
- Issue published online: 1 JUL 2007
- Article first published online: 1 JUL 2007
- Received Sep. 30, 1996; accepted for publication in revised form May 22, 1997.
- bladder cancer;
- bacillus Calmette-Guerin;
- systemic immunity;
- peripheral blood lymphocyte subsets
Background: Intravesical bacillus Calmette-Guérin (BCC) therapy for superficial bladder cancer induces obvious local immunological responses. The purpose of this study was to examine the systemic immunological influences induced by intravesical BCG therapy.
Methods: We measured peripheral blood lymphocyte subsets (PBLS) and monocyte counts in 30 patients with superficial bladder carcinoma by two-colored flow cytometry before, during, and after intravesical BCG treatment. Comparisons were made between 24 good treatment responders and 6 poor responders.
Results: From 3 to 12 months after the beginning of treatment, PBLS and monocyte counts changed, as evidenced by an increase of suppressor T cells and a decrease of helper T cells. The good responders had higher cell counts than the poor responders, with differences in cell counts between good and poor responders more marked 1 month after beginning treatment, particularly of natural killer cells, cytotoxic T cells, and inducer T cells. These differences disappeared 3 months after the onset of treatment.
Conclusion: Intravesical BCG therapy caused a marked and persistent alteration of the systemic immunological status.